Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2017 /
Breast cancer therapy resistance mediated by FGFR amplification

5th - 9th Dec 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.12.17
Views: 1013
Rating:

Dr Luigi Formisano - Vanderbilt University Medical Center, Nashville, USA

Dr Luigi Formisano speaks with ecancer at SABCS 2017 about breast cancer therapy resistance mediated by FGFR amplification.

He describes the development from PDX mouse models to an initial group of 34 breast cancer patients who overexpress FGFR, which he links to anti-oestrogen and CDK 4/6 resistance, and how this could be tackled to improve patient response.

Dr Formisano identifies ongoing trials to further validate these findings.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation